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THE granulocyte colony-stimulating factor (G-CSF)
plays an important role in normal granulopoiesis.
Its functions are mediated by specific receptors on
the surface of responsive cells and, upon ligand
binding, several cytoplasmic tyrosine kinases are
activated. The cytoplasmic region proximal to the
membrane of the G-CSF receptor (G-CSF-R) trans-
duces proliferative and survival signals, whereas the
distal carboxy-terminal region transduces matura-
tion signals and suppresses the receptor’s prolifera-
tive signals. Mutations in the G-CSF-R gene resulting
in truncation of the carboxy-terminal region have
been detected in a subset of patients with severe
congenital neutropenia who developed acute myelo-
genous leukemia (AML). In addition, the AML1-ETO
fusion protein, expressed in leukemic cells harboring
the t(8;21), disrupt the physiological function of
transcription factors such as C/EBPa and C/EBPo,
which in turn deregulate G-CSF-R expression. The
resulting high levels of G-CSF-R and G-CSF-dependent
cell proliferation may be associated with pathogen-
esis of AML with t(8;21). Moreover, in vitro and in
vivo studies demonstrated that G-CSF may act as a
co-stimulus augmenting the response of PML-RARa
acute promyelocytic leukemia cells to all-trans-
retinoic acid treatment. Finally, in the PLZF-RARa
acute promyelocytic leukemia transgenic model,
G-CSF deficiency suppressed leukemia develop-
ment. Altogether, these data suggest that the G-CSF
signaling pathway may play a role in leukemogen-
esis.
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Introduction
The term acute myelogenous leukemia (AML) refers
to a group of neoplastic disorders characterized by
the transformation of immature progenitors of the
bone marrow, which exhibit morphological and
immunophenotypic features common to the myeloid
lineage. An important characteristic common to all
subtypes of AML is the block of differentiation.
Genetically, AML results from acquired mutations,
frequently associated with chromosomal transloca-
tions, resulting in the generation of chimeric genes
and fusion proteins.
1 In most of the fusion genes
associated with AML pathogenesis, one of the in-
volved genes encodes for a transcription factor,
which is physiologically involved in hematopoietic
differentiation. In other cases, in the absence of
chromosomal translocations, the transcription factors
themselves are mutated. Therefore, the most com-
mon genetic mechanism that is associated with AML
is the aberrant expression of a transcription factor or
the production of an abnormal hybrid transcription
factor.
2
The granulocyte colony-stimulating factor (G-CSF)
is a cytokine secreted by the stromal cells of the
hematopoietic organs that influence the survival,
proliferation and differentiation of myeloid progeni-
tors.
3 The responsiveness of AML cells to G-CSF has
been reported extensively.
4 The spontaneous in vitro
proliferation of AML blasts and their growth response
greatly vary and do not depend on the number or
affinity of the growth factor. Particularly, AML cells
harboring the t(15;17) or the t(8;21) may differentiate
upon G-CSF administration.
5 8 Moreover, mutations
on the G-CSF receptor (G-CSF-R) detected in patients
with severe congenital neutropenia (SCN) who
developed AML suggest that the deregulation of this
pathway may contribute to leukemogenesis.
9 11
Finally, recent data demonstrated that transgenic
mice expressing the t(11;17)/acute promyelocytic
leukemia (APL)-associated fusion protein PLZF-
RARa depend on G-CSF stimulus in order to develop
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145full-blown leukemia. This review discusses the cur-
rent state of knowledge regarding the role of G-CSF
in leukemogenesis.
Molecular mechanisms of G-CSF action
In vitro low concentrations of G-CSF stimulate the
formation of granulocyte colonies exclusively,
whereas higher concentrations can also stimulate
small number of macrophage and mixed macro-
phage/granulocyte colonies. In addition, G-CSF en-
hances mature neutrophil function, including their
antibody-dependent cellular cytotoxicity and their
fMLP-induced superoxide production.
12,13 Therefore,
G-CSF seems to be responsible for both a ‘steady-
state’ and ‘emergency-state’ neutrophil production. In
humans, for example, low neutrophil counts co-exist
with high serum G-CSF levels in some clinical
situations, suggesting a homeostatic regulatory func-
tion for this growth factor.
14 On the other hand, when
extra neutrophils are required acutely, such as during
infections, G-CSF concentrations increase dramati-
cally (from less than 100 pg/ml up to 2000 pg/ml),
thus acting as an emergency factor by augmenting
granulopoiesis. In fact, endotoxins as wells as in-
flammatory mediators cause an increase of the
transcription of the G-CSF gene and of the release
of active G-CSF protein.
15
The biologic functions of G-CSF are mediated by
specific receptors on the surface of responsive cells.
The G-CSF-R, a single polypeptide containing 813
amino acids, is a member of the cytokine receptor
superfamily. G-CSF-R forms homo-oligomeric com-
plexes upon binding of a ligand. Like all members of
the cytokine receptor superfamily, G-CSF receptor
lacks intrinsic tyrosine kinase activity but can activate
cytoplasmic tyrosine kinases. Signal transduction
pathways that involve Janus tyrosine kinases (Jak1,
Jak2, and Tyk2) and signal transducer and activator of
transcription proteins (STAT1, STAT3, and STAT5) are
linked to the G-CSF receptor.
16,17 The cytoplasmic
region of the G-CSF-R can be divided in two
functional domains: membrane-proximal and mem-
brane-distal */ the first of which contains two
conserved subdomains named boxes 1 and 2,
whereas the membrane distal contains a less con-
served box 3 sequence.
18 In addition, there are four
tyrosine (Y) residues at positions 704, 729, 744 and
764 (three of them in the membrane-distal domain),
which are rapidly phosphorylated upon G-CSF bind-
ing, leading to the formation of potential binding sites
for signaling molecules that contain Src homology 2
or phosphotyrosine-binding domains.
18
Proliferation signals from G-CSF-R are predomi-
nantly mediated via Y704 and Y764, with a minor
contribution from Y744.
19 The formation of Grb2/
SHP-2, Gr2/p90 and Grb2/Shc/p140 complexes in
response to G-CSF binding is mediated by Y764,
whereas Y704 is a direct docking site for SHP-2.
20
The proliferative response to G-CSF depends mainly
on the STATs pathways, STAT5 being a key med-
iator, since its inhibition in 32Dc13 cells is able
to reverse proliferation without affecting differentia-
tion.
21
Survival and differentiation signals from G-CSF-R
are mainly transduced by Y704 and Y744, with a
lesser contribution from Y729, and correlates with the
capacities of these tyrosines to activate STAT3. How-
ever, at high G-CSF concentrations, other survival
mechanisms also are activated such as PI3-kinase and
mitogen-activated protein kinase.
19
The most revealing approach to define the in vivo
role of hematopoietic growth factors is to study the
phenotype of mice genetically deficient in these
factors. Murine models of factor deficiency have
been reported for monocyte-CSF, granulocyte /
monocyte (GM)-CSF and G-CSF.
22 24 The biologic
activities of the hematopoietic growth factors G-CSF
and GM-CSF overlap significantly both in vitro and
after pharmacologic administration in vivo. However,
mice deficient in each of these factors have char-
acteristic features. G-CSF-deficient mice have re-
duced hematopoietic progenitors in the bone
marrow and spleen and neutropenia. These animals
are markedly predisposed to spontaneous infections,
have a reduced long-term survival and a high
incidence of reactive type AA amyloidosis.
24 GM-
CSF-deficient mice manifest no detectable deficiency
in steady-state hematopoiesis, but have increased
splenic hematopoietic progenitors and impaired
pulmonary surfactant clearance resulting in abnorm-
alities resembling human alveolar proteinosis. They
also have a modest impairment of reproductive
capacity, a propensity to develop lung and soft tissue
infections, and a similarly reduced survival as in G-
CSF-deficient animals.
25 These contrasting pheno-
types do not exclude the occurrence of additional
redundant functions. The residual granulopoiesis in
G-CSF-deficient mice, for example, may be attributed
to GM-CSF. Moreover, the normal neutrophil level in
GM-CSF-deficient animals does not mean that GM-
CSF has no physiologic function in steady-state
granulopoiesis, but indicates that in the presence of
regulators such as G-CSF any such role is dispensa-
ble. Later studies generated mice lacking both G-CSF
and GM-CSF, which demonstrated phenotypic and
pathologic features consistent with the additive
effects of the constituent genotypes. Thus, these
animals manifest a high incidence of soft-tissue and
pulmonary infections, and a mortality rate signifi-
cantly greater than either of the singly deficient
strains. Some additional features may also be ob-
served: a greater degree of neutropenia among
newborn mice than in those lacking G-CSF alone,
L. Lobo de Figueiredo et al.
146 Mediators of Inflammation Vol 13  2004an increased neonatal mortality rate, and a dominant
influence of the lack of G-CSF on splenic hematopoi-
esis resulting in reduced numbers of splenic progeni-
tors.
25 These data provide an opportunity to assess
the role of these growth factors in normal hemato-
poiesis and help to understand the consequences of a
single factor deficiency.
Acquired G-CSF receptor mutations in SCN
A number of studies suggest that an abnormal
response of granulocytic progenitor cells to G-CSF
may be involved in the pathogenesis of SCN. This
disorder, also named Kostmann’s syndrome, is char-
acterized by persistent neutropenia and bone marrow
maturation arrest of neutrophil precursors at the
promyelocytic or myelocytic stage.
17 It occurs as
both an autosomal recessive or dominant disorder,
but many more sporadic than inherited cases have
been reported. Patients, usually children, have severe
neutropenia (absolute blood neutrophil count less
than 0.2  /10
9/l) and may die from infectious diseases
in their early life.
10 Pharmacologic administration of
G-CSF increases neutrophil blood counts and enables
long-time survival, but approximately 10 /15% of the
patients develop secondary myelodisplastic syn-
drome or AML.
11 The fact that precursor cells from
most of these patients retain some capacity to
proliferate suggests that no defect in maturation, a
characteristic of AML, is present in SCN. Thus, it is
possible that an impairment in the signaling pathway
through the G-CSF receptor may contribute to the
pathogenesis of this condition.
Mutations in the G-CSF receptor gene resulting in
truncation of the carboxy-terminal region have been
detected in a subset of patients with SCN and AML
evolving from SCN.
9,10,17 These mutations, detected
in cells of the myeloid lineage only, have been found
to localize to a critical cytoplasmic region spanning
nucleotides 2384 /2429 of the G-CSF receptor, and
lead to truncation of the distal cytoplasmic region of
the G-CSF receptor, rendering cells hypersensitive to
G-CSF. So far, five types of truncation mutations have
been found and there has been some controversy
over their involvement in the pathogenesis of SCN
among the various published studies.
Mitsui et al.
17 generated transgenic mice (TM)
expressing the mutant G-CSF receptor equivalent to
truncations at amino acids 718 and 731 in human G-
CSF receptor, those previously reported to be related
to transformation to myelodisplastic syndrome/AML
in SCN. Both of the mutant receptor TM had one-third
of peripheral neutrophil cell counts compared with
wild-type receptor TM, and also showed impaired
resistance to the infection with Staphylococcus aur-
eus. Moreover, the bone marrow of these TM had an
increased percentage of immature myeloid cells,
which is a feature of SCN. Hypersensitivity of myeloid
progenitors to stimulation with G-CSF was also
observed in the truncated G-CSF TM. These results
suggest the involvement of mutations in the G-CSF
receptor in the pathogenesis of SCN and prolonged
myeloid cell survival under G-CSF stimulation. This
latter effect may induce proliferative stress to myeloid
progenitors, and additional oncogenic events could
underlie the development of AML in patients with
antecedent SCN.
Aprikyan et al.
10 described cellular and molecular
studies of 12 SCN patients, including five patients that
evolved to develop AML, that revealed impaired
proliferative characteristics and accelerated apoptosis
of bone marrow progenitors cells in SCN compared
with 11 healthy controls as demonstrated by flow
cytometry analysis. This study also revealed hetero-
zygous deletion or substitution mutations in the
neutrophil elastase (NE) gene in nine of 12 patients
comparing with controls. The authors conclude that
the impaired survival of myeloid progenitor cells is
probably driven by the expression of mutant NE,
which may be the cellular mechanism responsible for
neutropenia in SCN. Finally, they suggest that
acquired G-CSF mutations may initiate signaling
events that override the pro-apoptotic effect of
mutant NE in primitive progenitor cells, resulting in
an expansion of the abnormal AML clone. This
statement is in accordance with Hunter and Avalos,
9
who have showed that mutations in the G-CSF
receptor in SCN/AML confer resistance to apoptosis
and enhance cell survival, events mediated by
activation of PI3-kinase and its downstream targets
Akt and Bad, in response to G-CSF. This extension of
cell survival would permit the acquisition of addi-
tional oncogenic events that could lead to develop-
ment of AML.
G-CSF in AML with t(8;21)/AML1-ETO
Approximately 5 /12% of AML cases harbor transloca-
tions between chromosomes 8 and 21 [t(8;21)(q22;
q22)] that generate the AML1-ETO chimeric gene.
26
The AML1-ETO fusion protein blocks normal granu-
locytic differentiation through the disruption of the
function of a transcription factor named CCAAT
enhancer binding protein a (C/EBPa).
27 C/EBPa
function is essential to normal granulocytopoiesis as
demonstrated by the fact that the non-conditional
inactivation of the C/EBPa gene in mice (knockout)
led to the complete absence of mature granulocytes,
without affecting other lineages, including mono-
cytes. Conversely, the enforced expression of
C/EBPa in bipotential myeloid progenitors resul-
ted in induction of granulocytic differentiation and
inhibition of monocytic development.
28 There are
two hypothetical models of the mechanism through
G-CSF and leukemogenesis
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tion: (a) AML1-ETO fusion protein can recognize
and bind to the AML1 binding site on DNA and
recruit co-repressors resulting in the inhibition of the
physiological activation of promoters of granulocytic
specific genes by C/EBPa; or (b) AML1-ETO can
inhibit a positive feedback loop exerted by C/
EBPa on its own expression (positive autoregulation)
(Fig. 1).
2 Corroborating with the second hypothesis is
the detection of decreased C/EBPa RNA levels in
t(8;21) patients.
27 Among the target genes of C/EBPa
are G-CSF-R, IL-6, E2F, c-MYC and defensin.
2 Inter-
estingly, G-CSF treatment can lead to in vitro and in
vivo differentiation of t(8,21) AML cell samples.
Shimizu et al.
29 showed that AML1-ETO might mod-
ulate cell responses to G-CSF since cells transfected
with this fusion protein showed increased prolifera-
tion in response to G-CSF without differentiating into
mature granulocytes. Moreover, the ectopic expres-
sion of AML1-ETO was found to induce the expres-
sion of G-CSF receptor, an effect that does not seem to
depend on the AML1-binding sequence, but on the C/
EBP binding site.
In addition to C/EBPa, another C/EBP isoform that
is deregulated by AML1-ETO is the C/EBPo, which is
almost exclusively expressed in the granulocytic
lineage and preferentially up-regulated during gran-
ulocytic differentiation. The expression of C/EBPo
was significantly up-regulated in the cells ectopically
expressing AML1-ETO (Fig. 1). The overexpression of
C/EBPo induced expression of G-CSF receptor and G-
CSF-dependent cell proliferation. High levels of G-
CSF receptor expression might provide leukemia
cells a growth advantage, and may also suppress
apoptosis.
29 However, this up-regulation of G-CSF
receptor does not completely explain all the effects of
AML1-ETO in leukemogenesis. It is possible that
additional factors, whose expression would be de-
regulated by AML1-ETO, are required to fully express
its transforming activity.
G-CSF and APL
APL is a distinct-subtype of AML that corresponds to
the M3 and M3 variant of the French American British
classification and to AML subtype with
t(15;17)(q22;q12) and variants according to World
Health Organization. APL is characterized by: (a) its
invariable association with reciprocal and balanced
translocations always involving the retinoic receptor
a (RARa) gene locus on chromosome 17q21; (b) the
clonal expansion of myeloid precursors presenting a
block of differentiation at the promyelocytic stage;
and (c) its unique sensitivity to the differentiating
action of the all-trans-retinoic acid (ATRA). At the
molecular level, the RARa gene on chromosome 17
can be fused to the promyelocytic leukaemia gene
(PML), to the promyelocytic leukaemia zinc finger
(PLZF) gene, to the nucleophosmin (NPM) gene, to
the nuclear mitotic apparatus (NuMA) gene, or to the
signal transducer and activator of transcription 5B
(STAT 5B) gene located on chromosome 15, chromo-
some 11, chromosome 5, chromosome 11, or chro-
mosome 17, respectively. In the vast majority of APL
cases, the t(15;17)/PML-RARa is involved and ATRA
treatment induces long-term remissions. However,
the rare APL cases harboring the t(11;17)/PLZF-RARa
FIG. 1. Hypothetical models of the mechanisms through which AML1-ETO fusion protein disrupt CEBPa function. AML1-ETO
can recruit repressor complexes to AML1 binding sites on the promoter regions of granulocytic speciﬁc genes and/or inhibit a
positive feedback loop exerted by C/EBPa on its own promoter. Both mechanisms lead to the decrease of C/EBPa
transcriptional activity and block of granulocytic differentiation. In addition, AML1-ETO may induce up-regulation of C/EBPo
which by its turn lead to overexpression of the G-CSF receptor and provide the leukemic cells with proliferative advantage.
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30
The expression of the G-CSF-R, as well as the
proliferative response induced by G-CSF, is higher in
APL cells compared with other AML subtypes.
5 In
vitro studies have shown that induction of differen-
tiation of PML-RARa-positive cells by ATRA can be
enhanced when G-CSF is applied as a co-stimulus.
6
Cassinat et al.
31 reported that G-CSF in combination
with retinoic acid enhanced the terminal differentia-
tion of fresh t(15;17)-positive APL blasts. Katayama
et al.
5 described the achievement of complete remis-
sion with G-CSF treatment in an APL patient resistant
to both cytotoxic agents and ATRA. The finding that
APL cells are exquisitely responsive to G-CSF sup-
ports the view that G-CSF is useful for augmentation
of their vulnerability to cell-cycle specific agents.
5
Jansen et al.
32 studied a patient with a t(11;17)-
positive APL and determined that the combined use
of ATRA and G-CSF could overcome the maturation
block of the leukemic cells. With retinoic acid and G-
CSF treatment alone, complete granulocytic matura-
tion of the leukemic cells occurred in vivo, followed
by a complete cytogenetical and hematological
remission. Bone marrow and blood became negative
in fluorescence in situ hybridization analysis, and
semi-quantitative polymerase chain reaction showed
a profound reduction of PLZF-RARa. The response
was transient, as fluorescence in situ hybridization-
positive cells reappeared in the bone marrow after 7
weeks of treatment. This study suggests that t(11;17)-
positive leukemia cells are not intrinsically resistant to
retinoic acid and that the G-CSF co-stimulus may be
sufficient to render the cells ATRA sensitive.
TM expressing the PML-RARa fusion gene under
the control of the human cathepsin G promoter
(hCG-PML-RARa) develop a form of leukemia that
resembles human APL, presenting the characteristic
block of myeloid differentiation at the promyelocytic
stage and the sensitivity to ATRA treatment. In
contrast to leukemia in hCG-PML-RARa TM, leuke-
mia in hCG-PLZF-RARa TM lacks the distinctive block
of differentiation at the promyelocytic stage of
myelopoiesis and is characterized by leukocytosis
and infiltration of all organs by terminally differen-
tiated myeloid cells (a picture that resembles human
chronic myeloid leukemia). In both TM models,
leukemia develops after a long latency. Moreover,
hCG-PLZF-RARa TM do not respond to RA treat-
ment.
33
Lieschke et al.
34 analyzed the relevance of G-CSF
and GM-CSF stimuli for leukemia development in
hCG-PLZF-RARa TM. By crossing these TM with
knockout mice for either G-CSF (G-CSF
 / ) or GM-
CSF (GM-CSF
 / ), mutants deficient in either growth
factor were obtained. The survival data suggested
that while wild-type hCG-PLZF-RARa and GM-
CSF
 /  hCG-PLZF-RARa mice developed the char-
acteristic transgene-induced leukemia, G-CSF
 / 
hCG-PLZF-RARa mice did not succumb to leukemia
and survived indistinguishably from G-CSF
 /  con-
trols.
34 This experiment has demonstrated that aber-
rant endogenous G-CSF signals seem to be essential
for modifying the leukemogenic propensity of fusion
genes like PLZF-RARa. This suggests that therapeutic
approaches exploring G-CSF as a co-stimulus may be
useful for the treatment of some leukemias.
In fact, Lowenberg et al.
35 recently published a
study including 640 adult AML patients who were
randomized to receive or not receive G-CSF before
and during their first two courses of chemotherapy.
Although the remission rates were similar in both
groups, increased overall survival, disease-free survi-
val as well as event-free survival were observed in the
G-CSF-treated group. The benefit of chemotherapy-
sensitization by G-CSF was particularly evident
among the intermediate-risk subset of patients. Un-
fortunately, G-CSF priming did not improve the
outcome among patients with chemotherapy-refrac-
tory, unfavorable-risk AML.
35 Nevertheless, these
results encourage the strategy of using G-CSF priming
to extinguish subpopulations of leukemic cells rela-
tively insensitive to chemotherapy and reduce the
risk of relapse.
Conclusion
Although the relevance of G-CSF in the regulation of
granulopoiesis is well established, and much of the
molecular mechanisms underlying its function has
been elucidated, only recently scientific evidence has
been gathered to suggest that acquired mutations in
G-CSF-R, or the disruption of the G-CSF function by
leukemogenic fusion proteins, may contribute to
leukemogenesis. In addition, therapeutic approaches
using G-CSF to mobilize subpopulations of leukemic
cells, rendering them sensitive to chemotherapy, may
represent an important progress in leukemia treat-
ment.
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